Noven Pharms Inc patents expiration
1. Daytrana patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9034370 | NOVEN PHARMS INC | Device for transdermal administration of drugs including acrylic polymers |
Oct, 2025
(2 years from now) | |
| US9668981 | NOVEN PHARMS INC | Device for transdermal administration of drugs including acrylic based polymers |
Oct, 2025
(2 years from now) | |
| US8632802 | NOVEN PHARMS INC | Device for transdermal administration of drugs including acrylic polymers |
Oct, 2025
(2 years from now) | |
Drugs and Companies using METHYLPHENIDATE ingredient
Market Authorisation Date: 06 April, 2006
Treatment: Method for transdermally delivering a drug to a user in need thereof
Dosage: FILM, EXTENDED RELEASE;TRANSDERMAL
DAYTRANA family patents
2. Xelstrym patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8632802 | NOVEN PHARMS INC | Device for transdermal administration of drugs including acrylic polymers |
Oct, 2025
(2 years from now) | |
| US9034370 | NOVEN PHARMS INC | Device for transdermal administration of drugs including acrylic polymers |
Oct, 2025
(2 years from now) | |
| US8591941 | NOVEN PHARMS INC | Transdermal drug delivery device including an occlusive backing |
Oct, 2025
(2 years from now) | |
| US9456993 | NOVEN PHARMS INC | Compositions and methods for transdermal delivery of amphetamine |
Oct, 2033
(10 years from now) | |
| US9474722 | NOVEN PHARMS INC | Compositions and methods for transdermal delivery of amphetamine |
Oct, 2033
(10 years from now) | |
| US11559501 | NOVEN PHARMS INC | Transdermal amphetamine compositions with low levels of carbamate |
Jan, 2042
(18 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product (NP) | Mar 22, 2025 |
Drugs and Companies using DEXTROAMPHETAMINE ingredient
Market Authorisation Date: 22 March, 2022
Treatment: A method of treating attention deficit hyperactivity disorder by administering a transdermal composition containing amphetamine
Dosage: SYSTEM;TRANSDERMAL
XELSTRYM family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic